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Abstract: Of the classes of pharmacotherapy for seasonal allergic rhinitis, intranasal 
corticosteroids are the preferred treatment and are recommended in practice guidelines as first-line 
pharmacotherapy for rhinitis with prominent nasal congestion. The enhanced-affinity intranasal 
corticosteroid fluticasone furoate nasal spray (GW685698X), is one of the newest additions to the 
armamentarium for allergic rhinitis. This review summarizes the preclinical and clinical data on 
fluticasone furoate nasal spray and discusses its place in pharmacotherapy for seasonal allergic 
rhinitis. Important attributes of fluticasone furoate in seasonal allergic rhinitis include low systemic 
bioavailability (,0.5%), onset of symptom relief as early as eight hours after initiation of treat-
ment, 24-hour symptom relief with once-daily dosing, comprehensive coverage of both nasal 
and ocular symptoms, safety and tolerability with daily use, and availability in a side-actuated 
device that makes medication delivery simple and consistent. With these attributes, fluticasone 
furoate nasal spray has the potential to enhance patient satisfaction and compliance and reduce 
the need for polypharmacy in the management of seasonal allergic rhinitis.
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Introduction
Allergic rhinitis, which affects approximately one in five Americans,1 is an inflammatory 
disease caused by an IgE-mediated immune response to inhaled allergens at the nasal 
mucosa. Onset of allergic rhinitis is most common in childhood with a mean age of 
onset of 8–11 years, but allergic rhinitis occurs in people of all ages.2 The disease 
affects boys more often than girls in childhood, but affects the sexes nearly equally 
in adulthood.2 Allergic rhinitis is characterized by nasal symptoms of congestion, 
rhinorrhea, sneezing, and ocular symptoms of redness, tearing, and itching,3 and it 
can be complicated by comorbidities including asthma, sinusitis, and otitis media.4 
Symptoms disturb sleep, cause fatigue, and impair concentration. These effects may 
underlie the negative effects of allergic rhinitis on productivity and quality of life.1,5–8 
Each year in the US, an estimated 3.5 million work days and two million school days 
are lost because of allergic rhinitis,1 and estimated annual direct and indirect costs of 
up to $4.9 billion and $9.7 billion, respectively, are incurred.9
Pharmacotherapy for allergic rhinitis includes intranasal corticosteroids and 
antihistamine-decongestant combinations, as well as the less commonly used 
decongestants alone, intranasal anticholinergics, oral, intranasal, and intraocular 
antihistamines, and mast cell stabilizers. Of these classes of therapy, intranasal 
corticosteroids are the preferred treatment for seasonal allergic rhinitis and are 
recommended in both the American Academy of Allergy, Asthma and Immunology Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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guidelines and the World Health Organization Allergic 
Rhinitis and Impact on Asthma guidelines as the first 
line of pharmacotherapy for rhinitis with prominent nasal 
congestion, which is the most bothersome symptom of allergic 
rhinitis.3,10 Only intranasal corticosteroids have proven 
anti-inflammatory activity against the pathophysiologic 
aspects of both early- and late-phase allergic reactions and 
are effective for the range of nasal symptoms.10–12 In that 
intranasal corticosteroids inhibit the inflammatory process 
mediating nasal symptoms and consistently alleviate nasal 
congestion, they differ from oral antihistamines, which are 
not particularly effective for nasal congestion. In addition, 
systemic drug exposure and corresponding risk of systemic 
side effects are minimal with intranasal corticosteroids.
The enhanced-affinity intranasal corticosteroid fluticasone 
furoate nasal spray (GW685698X) is one of the newest 
additions to the armamentarium for allergic rhinitis. 
Fluticasone furoate was introduced in 2007 as Veramyst® in 
the US, where it is indicated for treatment of symptoms of 
seasonal and perennial allergic rhinitis in adults and children 
two years and older. In Europe, fluticasone furoate is marketed 
as Avamys® and is indicated for the treatment of symptoms 
of allergic rhinitis in adults and children six years and older. 
Fluticasone furoate is a new molecular entity that differs 
from other corticosteroid molecules, including fluticasone 
propionate and mometasone furoate. Important attributes of 
fluticasone furoate in seasonal allergic rhinitis include very 
low systemic bioavailability (,0.5%), onset of symptom 
relief as early as eight hours after initiation of treatment, 
24-hour symptom relief with once-daily dosing, compre-
hensive coverage of both nasal and ocular symptoms, safety 
and tolerability with daily use, and availability in a novel, 
side-actuated delivery device designed to make medication 
delivery simple and consistent. This review summarizes the 
preclinical and clinical data on fluticasone furoate nasal 
spray and discusses its place in pharmacotherapy for allergic 
rhinitis.
Fluticasone furoate
Pharmacology
Fluticasone furoate is a synthetic fluorinated corticosteroid 
(Figure 1) with anti-inflammatory effects arising from its 
interaction with intracellular glucocorticoid receptors.13 An 
enhanced-affinity corticosteroid, fluticasone furoate has greater 
relative receptor affinity in vitro for the human glucocorticoid 
receptor than other corticosteroids including dexamethasone, 
mometasone furoate, fluticasone propionate, ciclesonide 
active principle, and budesonide (Figure 2).14 The precise 
mechanism of action of fluticasone furoate in allergic rhinitis 
is not definitively known but is thought to arise from one or 
more of the wide-ranging anti-inflammatory effects it shares 
with other corticosteroids, which act on multiple inflammatory 
cell types (eg, mast cells, eosinophils, neutrophils, mac-
rophages, lymphocytes) and affect multiple inflammatory 
mediators (eg, histamine, eicosanoids, leukotrienes, cytok-
ines).15 In in vitro experimental models, fluticasone furoate 
demonstrated potent glucocorticoid activity in two pathways, 
namely the nuclear factor-κβ pathway and the transactivation 
glucocorticoid response element pathway, that are downstream 
of the glucocorticoid receptor and thought to be relevant to 
anti-inflammatory activity in allergic rhinitis.14 In addition, 
fluticasone furoate potently inhibited the proinflammatory 
cytokine tumor necrosis factor-alpha and was more effective 
at preserving epithelial integrity and reducing epithelial 
permeability in response to protease- and mechanical-induced 
cell damage than other corticosteroids in vitro.14 In studies 
with isolated human bronchial epithelial cells, fluticasone 
furoate demonstrated the greatest cellular accumulation and 
the slowest flux across cellular membranes compared with 
other corticosteroids for allergic rhinitis but incorporated easily 
into the cells, properties that are consistent with greater tissue 
retention and a long duration of action.14
Drug delivery device and dosing
Fluticasone furoate nasal spray is an aqueous suspension of 
micronized fluticasone furoate for topical administration to 
the nasal mucosa. It is delivered by a side-actuated, short-
nozzle device developed to improve the ease of medication 
delivery and to minimize variability of the actuated dose.16,17 
This device was developed based on extensive studies 
of the preferences of patients and physicians who ranked 
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Figure 1 Chemical structure of fluticasone furoate: (6α,11β,16α,17α)-6,9-difluoro-
17-{[(fluoro-methyl)thio]carbonyl}-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-
17-yl 2-furancarboxylate.15Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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multiple candidate devices.16 The current delivery device was 
consistently preferred for its design, which renders it easy to 
hold and operate, and its fine, consistent mist, which facilitates 
comfortable dispersion of the drug in the nasal cavity.16
Each actuation of the device delivers 27.5 µg of 
fluticasone furoate in 50 µL of suspension (0.015% w/w 
benzalkonium chloride, dextrose anhydrous, edetate 
disodium, microcrystalline cellulose, carboxymethylcellulose 
sodium, polysorbate 80, and purified water).13 The device 
delivers a low spray volume to minimize the amount of drug 
that runs down the back of the throat or leaks from the nose. 
Fluticasone furoate had the lowest application volume per 
spray in a study of several aqueous corticosteroids including 
budesonide, triamcinolone acetonide, fluticasone propionate, 
and mometasone furoate.18
Fluticasone furoate is administered once daily. According 
to the US prescribing information, in those 12 years of age 
and older, the recommended starting dosage is 110 µg once 
daily administered as two sprays (27.5 µg /spray) in each 
nostril.15 In children aged 2–11 years, the recommended 
starting dosage in the US is 55 µg once daily administered 
as one spray (27.5 µg /spray) in each nostril, with the option 
to increase to 110 µg (two sprays in each nostril) once daily 
in the event of inadequate response to 55 µg once daily.
Pharmacokinetics
Fluticasone furoate nasal spray has low systemic exposure. 
Because the minimal amount of fluticasone furoate swallowed 
after intranasal administration is subject to extensive first-
pass metabolism, systemic bioavailability is negligible.13 
Fluticasone furoate administered intranasally to 16 healthy 
volunteers at supratherapeutic dosages of 880 µg at eight-hour 
intervals for 10 doses, or 2640 µg /day, had a geometric mean 
absolute bioavailability of 0.50% (90% confidence interval [CI] 
0.34%–0.74%).19 Except in isolated cases, fluticasone furoate 
is not quantifiable in plasma following intranasal dosing of 
110 µg once daily.13,15 Even after administration of a 2 mg oral 
dose in a study in healthy volunteers, bioavailability was low 
(1.6%) because of extensive first-pass metabolism.20
The first-pass metabolism of fluticasone furoate is 
mediated by cytochrome (CYP) 3A4.15 Potent inhibitors of 
CYP 3A4 have the potential to increase systemic exposure 
to fluticasone furoate and thereby to increase the risk of 
systemic side effects, such as adrenal suppression. In a 
drug interaction study, six of 20 subjects coadministered 
fluticasone furoate nasal spray and the CYP 3A4 inhibitor 
ketoconazole (200 mg once daily) for seven days had low, 
but measurable, levels of fluticasone furoate compared with 
one of 20 subjects coadministered fluticasone furoate and 
placebo.15 Serum cortisol concentrations were reduced over 
24 hours by approximately 5% in subjects who received 
ketoconazole with fluticasone furoate compared with subjects 
who received placebo with fluticasone furoate.
Efficacy
Fluticasone furoate nasal spray has been demonstrated to 
be significantly more effective than placebo at relieving 
symptoms of both seasonal allergic rhinitis and perennial aller-
gic rhinitis in children, adolescents, and adults in double-blind, 
controlled clinical studies.21–29 This section describes efficacy 
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data from randomized, double-blind, placebo-controlled 
studies in seasonal allergic rhinitis in patients sensitized to a 
variety of pollen types including mountain cedar, ragweed, and 
grass. In these studies, patients used a diary card to rate the 
severity of individual nasal symptoms of congestion, rhinor-
rhea, itching, and sneezing on a four-point scale ranging from 
0 (symptom not present) to 3 (symptom difficult to tolerate 
and interferes with activities of daily living and/or sleeping). 
Ocular symptoms of redness, itching/burning, and tearing/
watery eyes were assessed using the same four-point scale 
that was used for nasal symptoms. Patients rated these nasal 
and ocular symptoms on both a reflective basis each morning 
and evening and on an instantaneous basis each morning. The 
reflective rating provided information on symptom severity 
over the preceding 12 hours whereas the instantaneous rating 
provided information on symptom severity at the moment of 
the assessment. The morning predose instantaneous rating 
reflected symptoms at the end of the 24-hour dosing interval 
on every treatment day (except the first treatment day) because 
study medication was administered in the morning. At the 
final clinic visit in most studies, patients rated their overall 
response to therapy on a seven-point category scale (signifi-
cantly improved, moderately improved, mildly improved, no 
change, mildly worse, moderately worse, and significantly 
worse). Most studies also included the Rhinoconjunctivitis 
Quality of Life Questionnaire (RQLQ), administered at the 
beginning and the end of the treatment period. The RQLQ is 
a 28-item, self-administered, disease-specific instrument that 
assesses quality of life over a one-week interval.30
The primary endpoint was mean change from baseline 
in reflective total nasal symptom score in all studies except 
the active-comparator study involving fluticasone propi-
onate (GlaxoSmithKline protocol FFR100652, Table 1) 
and the active-comparator studies involving fexofenadine 
(GlaxoSmithKline protocols FFU109045 and FFU109047, 
Table 1).21,28 In the study comparing fluticasone furoate with 
fluticasone propionate, the primary endpoint was the sum of 
three individual symptom scores for sneezing + rhinorrhea + 
nasal congestion.21 These three symptoms are considered to 
be the major symptoms of allergic rhinitis in Japan, where 
the study was conducted. In the studies comparing fluticasone 
furoate with fexofenadine, the primary endpoint was night-
time symptoms score, described further in the Nighttime 
Symptoms section later in this paper.28
Nasal symptoms
Table 1 summarizes the effects of fluticasone furoate nasal 
spray on nasal symptoms of seasonal allergic rhinitis in 
randomized, double-blind, placebo-controlled studies.21–25,28,29 
Across studies, fluticasone furoate nasal spray 110 µg 
conferred comprehensive coverage of nasal symptoms, with 
significantly better results than placebo for congestion, rhin-
orrhea, itching, and sneezing. Fluticasone furoate nasal spray 
110 µg also conferred consistent coverage of nasal symptoms 
over time, with significantly better results than placebo for 
morning, evening, and daily reflective nasal symptom scores 
throughout the study periods. Onset of significant benefit 
versus placebo was observed as early as eight hours after 
initiation of treatment for reflective total nasal symptom scores. 
Furthermore, administered once daily, fluticasone furoate nasal 
spray 110 µg had sustained efficacy over the 24-hour dosing 
period, as demonstrated by significantly greater improvement 
compared with placebo in morning predose instantaneous total 
nasal symptom scores across studies.
Results for patient-rated overall response to therapy and 
on the RQLQ were consistent with the symptom scores in 
demonstrating significant benefits of fluticasone furoate 
nasal spray versus placebo (Table 1).22–25,28 Across trials 
employing the RQLQ, the improvement in RQLQ score 
with fluticasone furoate versus placebo met or exceeded the 
minimally important difference (the threshold for being clini-
cally relevant) of 0.5 points (Table 1). In a pooled analysis of 
four of these double-blind, placebo-controlled trials (Glaxo-
SmithKline protocols FFR20001, FFR30003, FFR103184, 
and FFR104861), the least square mean difference between 
fluticasone furoate and placebo was -0.690 (95% CI -0.84 to 
-0.54).31 RQLQ results were not reported in the manuscript 
based on GlaxoSmithKline protocol FFR10001024 (the study 
of children aged 2–11 years) or in the manuscript based 
on GlaxoSmithKline protocol FFR10065221 (conducted in 
Japan). For GlaxoSmithKline protocols FFU10904528 and 
FFU10904728 (comparator studies with fexofenadine), the 
Nocturnal RQLQ (NRQLQ) a 16-item, disease-specific 
instrument that assesses nocturnal quality of life over a one-
week interval, was used instead of the RQLQ as reported 
below.
Ocular symptoms
Table 1 summarizes the effects of fluticasone furoate nasal 
spray on ocular symptoms of seasonal allergic rhinitis in 
randomized, double-blind, placebo-controlled studies. Across 
prospective studies conducted during different allergy seasons 
and in different geographic regions throughout Europe and 
the US, fluticasone furoate nasal spray was significantly 
better than placebo in improving ocular symptoms of seasonal 
allergic rhinitis (Table 1).22–25,28 Efficacy for ocular symptoms Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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Fluticasone furoate in seasonal allergic rhinitis
has been observed, but not consistently, with other intranasal 
corticosteroids.32 In a review of 35 randomized, placebo-con-
trolled, clinical trials of seven intranasal corticosteroids in the 
treatment of seasonal allergic rhinitis, only fluticasone furoate 
nasal spray demonstrated significant benefit versus placebo 
on ocular symptoms in prospective studies (6/6 studies).32 
Beclomethasone dipropionate, budesonide, ciclesonide, flu-
ticasone propionate, mometasone furoate, and triamcinolone 
acetonide were not consistently effective versus placebo for 
ocular symptoms across studies.32 On the basis of these results, 
fluticasone furoate nasal spray has been characterized as the 
only intranasal corticosteroid with consistent efficacy for the 
ocular symptoms of seasonal allergic rhinitis.31,32
The efficacy of fluticasone furoate nasal spray for ocular 
symptoms is probably not attributed to systemic activity given 
the extremely low absolute bioavailability (,0.5%) of the 
drug. It has been hypothesized that intranasal corticosteroids 
improve ocular symptoms of allergic rhinitis by decreasing 
nasal inflammation and modulating allergen-induced reflex 
neuronal activity from the nose to the eye.33,34 Results of a 
double-blind, placebo-controlled, crossover study are con-
sistent with this hypothesis.35 In 20 patients with seasonal 
allergic rhinitis, nasal antigen challenge resulted in sneezing 
and other nasal symptoms, eye symptoms, increases in nasal 
secretion weights, and increases in percentages of eosinophils 
in nasal scrapings. Treatment with fluticasone furoate nasal 
spray reduced eosinophil infiltration and eye symptoms.
The receptor binding properties of fluticasone furoate have 
been suggested to account for its consistent efficacy for ocular 
symptoms compared with other intranasal corticosteroids.32 
Fluticasone furoate has greater affinity for the glucocorticoid 
receptor than other corticosteroids used intranasally and 
demonstrates prolonged receptor binding, properties that 
translate into greater potency than other corticosteroids in mod-
els of inflammation.14 The greater anti-inflammatory potency of 
fluticasone furoate as demonstrated in vitro might contribute to 
more consistent inhibition of the naso-ocular reflex in vivo.32
Nighttime symptoms
Nasal symptoms in allergic rhinitis have been strongly 
linked to sleeping difficulties and consequent impairment 
in next-day function and well-being.36–41 Pharmacotherapy-
mediated amelioration of nasal symptoms has been linked 
to improvements in sleep and next-day functioning.36–41 The 
effects of fluticasone furoate nasal spray on nighttime symp-
toms were assessed in two identically designed, randomized, 
double-blind, placebo-controlled studies in which patients 
received fluticasone furoate nasal spray 110 µg once daily 
(n = 312, study 1; n = 224, study 2), the oral antihistamine 
fexofenadine 180 mg daily (n = 311, study 1; n = 227, study 2), 
or placebo (n = 313, study 1; n = 229, study 2) for two weeks.28 
Each morning, patients completed a nighttime symptoms scale 
comprising three items, ie, nasal congestion upon awakening 
(rated on a scale from 0 [none] to 3 [severe]), difficulty in 
going to sleep because of nasal symptoms (rated on a scale 
from 0 [not at all difficult] to 3 [very difficult]), and night-
time awakenings because of nasal symptoms (rated on a scale 
from 0 [not at all] to 3 [I feel like I was awake all night]). The 
sum of scores for the three items is the nighttime symptoms 
score, a validated, clinically meaningful measure in patients 
with seasonal allergic rhinitis.42 In both studies, fluticasone 
furoate was significantly more effective (P , 0.001) than both 
placebo and fexofenadine with respect to mean changes from 
baseline in the nighttime symptoms score. Results for other 
efficacy endpoints are summarized in Table 1.
The improvements in nighttime symptoms during 
fluticasone furoate treatment were associated with statistically 
significant improvements in nocturnal rhinitis-specific quality 
of life measured with the NRQLQ.43 Besides the total NRQLQ 
score, the scores on each of the NRQLQ domains (sleep 
problems, sleep time problems, symptoms on waking in the 
morning, practical problems) were significantly better with 
fluticasone furoate nasal spray than fexofenadine or placebo.
Summary
Results of randomized, double-blind, placebo- and 
  comparator-controlled studies demonstrate that fluticasone 
furoate nasal spray provides comprehensive coverage of both 
nasal and ocular symptoms in seasonal allergic rhinitis caused 
by a variety of pollen types. It has also been demonstrated 
effective for nighttime symptoms of seasonal allergic rhinitis 
in two randomized, double-blind studies. With once-daily 
dosing, symptom coverage is maintained throughout the 
24-hour dosing interval.
Safety and tolerability
With intranasal corticosteroids, the occurrence of systemic side 
effects is limited by the targeted delivery of medication to its 
nasal mucosal site of action. The low potential of intranasal 
corticosteroids for causing systemic side effects has been 
established in both short- and long-term studies.3,11,12 In this 
respect, intranasal corticosteroids differ from oral corticos-
teroids, which have well documented adverse effects with 
chronic administration. This section reviews data on the safety 
and tolerability of fluticasone furoate nasal spray in patients 
with seasonal allergic rhinitis. Because data in patients with Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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perennial allergic rhinitis are also germane to the safety profile 
of fluticasone furoate nasal spray in seasonal allergic rhinitis, 
safety results of studies in perennial allergic rhinitis are also 
discussed when relevant. Studies in perennial allergic rhinitis 
involved longer treatment periods than studies in seasonal 
allergic rhinitis and thus constitute a more rigorous test of 
safety and tolerability than seasonal allergic rhinitis studies.
Adverse events
The clinical trials program for fluticasone furoate in seasonal 
and perennial allergic rhinitis provide extensive information on 
adverse events, defined as any untoward medical occurrence 
temporally associated with the use of a medicinal product in a 
patient, regardless of the suspected cause of that occurrence. 
Adverse event data on fluticasone furoate come from nine 
placebo-controlled clinical trials of 2–12 weeks’ duration in 
1563 patients with seasonal or perennial allergic rhinitis.15 
Six of the nine placebo-controlled trials enrolled 768 adoles-
cents and adults ( 12 years and older) treated with fluticasone 
furoate 110 µg once daily for 2–6 weeks. The remaining three 
placebo-controlled trials enrolled 795 children (2–11 years) 
treated with fluticasone furoate 55 µg or 110 µg once daily for 
2–12 weeks. Table 2 summarizes the frequencies of the most 
common adverse events. Regardless of age group, adverse 
events were reported with similar frequency with fluticasone 
furoate and placebo. The most common adverse event was 
headache. Less than 3% of patients discontinued treatment 
because of adverse events, and the rate of premature with-
drawal from fluticasone furoate was similar to or lower than 
the rate with placebo.
The adverse event profile of fluticasone furoate nasal 
spray was assessed in older children, from 6–11 years, in 
a subanalysis of data from three randomized, double-blind, 
  placebo-controlled, parallel-group studies, including a 
two-week efficacy and safety study in patients with sea-
sonal allergic rhinitis, a 12-week efficacy and safety study 
in patients with perennial allergic rhinitis, and a six-week 
safety study in patients with perennial allergic rhinitis.44 
Patients were treated with fluticasone furoate 55 µg 
(n = 297), fluticasone furoate 110 µg (n = 321), or placebo 
(n = 330). Across studies, the percentages of patients with 
adverse events considered by the investigator to be drug-
related were 10% with fluticasone furoate 55 µg, 7% with 
fluticasone furoate 110 µg, and 8% with placebo. The most 
common adverse events were headache (8% with 55 µg, 
9% with 110 µg, 8% with placebo), nasopharyngitis (5% 
with 55 µg, 6% with 110 µg, 5% with placebo), pharyngo-
laryngeal pain (5% with 55 µg, 3% with 110 µg, 4% with 
placebo), and epistaxis (4% with 55 µg, 4% with 110 µg, 
4% with placebo).
The adverse event profile of fluticasone furoate nasal spray 
has also been assessed with long-term daily use. Fluticasone 
furoate nasal spray was well tolerated in a randomized, double-
blind, placebo-controlled study (GlaxoSmithKline protocol 
FFR102123) involving 12 months of daily treatment of peren-
nial allergic rhinitis in 605 patients $12 years treated with 
fluticasone furoate 110 µg once daily and 201 treated with 
  placebo.45 The incidence of most adverse events with fluticasone 
furoate was similar to that with placebo, with the excep-
tion of epistaxis, which was more common with fluticasone 
furoate (20%) than placebo (8%). Of 123 events of epistaxis 
in patients treated with fluticasone furoate, 83 were mild, 
39 were moderate, and one was severe.15,45 All of the 17 events 
of epistaxis in patients treated with placebo were mild. No 
evidence of clinically relevant systemic corticosteroid exposure 
was observed in this study. The incidence of epistaxis in this 
study was within the range observed with other intranasal 
corticosteroids (ie, 17%–23%).46
Hypothalamic-pituitary-adrenal  
axis function
Bioavailable exogenous corticosteroids can sup-
press hypothalamic-pituitary-adrenal axis function.47 
Table 2 Adverse events in placebo-controlled clinical trials of 
fluticasone furoate in patients with seasonal or perennial allergic 
rhinitis15
Adolescents and adults age $ 12 years in trials lasting 2–6 weeks
Fluticasone furoate Placebo
110 μg  
n = 768
 
n = 774
n (%) n (%)
Headache 72 (9) 54 (7)
epistaxis 45 (6) 32 (4)
Pharyngolaryngeal pain 15 (2) 8 (1)
Nasal ulceration 11 (1) 3 (,1)
Back pain 9 (1) 7 (,1)
Pediatric patients aged 2–12 years in trials lasting 2–12 weeks
Fluticasone furoate Placebo
55 μg  
n = 369
110 μg  
n = 426
 
n = 429
n (%) n (%) n (%)
Headache 28 (8) 33 (8) 31 (7)
Nasopharyngitis 20 (5) 21 (5) 21 (5)
epistaxis 17 (5) 17 (4) 19 (4)
Pyrexia 17 (5) 19 (4) 7 (2)
Pharyngolaryngeal pain 16 (4) 12 (3) 14 (3)
Cough 12 (3) 16 (4) 12 (3)Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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The  risk  of  intranasal  corticosteroid-associated 
hypothalamic-pituitary-  adrenal axis suppression is low 
compared with that associated with the more bioavailable oral 
corticosteroids.48 Potential effects of fluticasone furoate nasal 
spray on hypothalamic-  pituitary-adrenal axis function have 
been assessed in several studies, none of which demonstrated 
an effect of the drug.18,49,50
The effects of fluticasone furoate nasal spray on hypothalamic-
pituitary-adrenal axis function as indexed by 24-hour urinary 
cortisol were assessed in a randomized, double-blind, parallel-
group, placebo-controlled study (GlaxoSmithKline protocol 
FFR20001).23 Patients took fluticasone furoate 55 µg (n = 127), 
110 µg (n = 127), 220 µg (n = 129), 440 µg (n = 130), or placebo 
(n = 128) once daily for two weeks. At baseline, mean 24-hour 
urinary cortisol values were comparable among treatment groups 
and fell within the normal range (ie, 2.1–38 µg/24 hours for 12- 
to 16-year-olds and 2.0–42.4 µg/24 hours for those .16 years 
old) in each treatment group (Table 3).23 At the end of the two-
week treatment period, treatment groups did not differ with 
respect to mean change in 24-hour urinary cortisol, the incidence 
of patients with values below the lower limit or above the upper 
limit of normal, or the incidence of shifts to below or above 
normal values (Table 3).23
This study, like most of the studies in patients with 
seasonal allergic rhinitis, involved a two-week treatment 
period. The effect of fluticasone furoate nasal spray on 
hypothalamic-pituitary-adrenal axis function have also 
been assessed in studies with six-week treatment periods in 
patients with perennial allergic rhinitis.49,50 In a randomized, 
double-blind, parallel-group, placebo- and prednisone-
controlled study in 112 patients 12 years of age and older 
with perennial allergic rhinitis, patients were administered 
fluticasone furoate 110 µg once daily, prednisone 10 mg once 
daily, or placebo for six weeks.49 Fluticasone furoate was 
noninferior to placebo with respect to the ratio from baseline 
in 24-hour serum cortisol weighted mean (treatment ratio 
0.98, 95% CI 0.89–1.07) whereas prednisone significantly 
reduced serum cortisol secretion versus placebo (treatment 
ratio 0.49, 95% CI 0.43–0.57). Fluticasone furoate did not 
differ from placebo with respect to 24-hour urinary cortisol 
excretion. In a randomized, double-blind, parallel-group, 
placebo-controlled study in 112 patients aged 2–11 years 
with perennial allergic rhinitis, patients were administered 
fluticasone furoate 110 µg once daily or placebo for six 
weeks.50 Fluticasone furoate was noninferior to placebo with 
respect to the ratio from baseline in 24-hour serum cortisol 
Table 3 Summary of data on 24-hour urinary cortisol excretion in the urine cortisol population* in a randomized, double-blind, 
placebo-controlled, two-week study (GlaxoSmithKline FFR20001)23
Fluticasone furoate Placebo
50 μg 100 μg 200 μg 400 μg
Baseline
n 116 118 121 120 117
Mean, µg /24 hours (SD) 21.9 (18.0) 21.3 (21.8) 22.4 (15.5) 20.4 (12.4) 20.0 (14.3)
Outside normal range, n (%) 
.Normal 
,Normal
 
13 (11) 
0 (0)
 
15 (13) 
5 (4)
 
12 (10) 
0 (0)
 
8 (7) 
0 (0)
 
8 (7) 
1 (1)
End of the treatment period
n 116 118 122 120 117
Mean, µg /24 hours (SD) 23.9 (23.1) 20.8 (18.3) 21.3 (16.4) 20.9 (14.9) 20.9 (18.7)
Mean change from baseline (SD) 2.0 (26.3) -0.5 (25.2) (1.2† (19.5) 0.6 (17.8) 0.9 (20.0)
Outside normal range, n (%) 
.Normal 
,Normal
 
15 (13) 
1 (1)
 
9 (8) 
2 (2)
 
16 (13) 
1 (1)
9 (8) 
1 (1)
 
11 (9) 
1 (1)
Shifts from baseline, n (%)
To low 1 (1) 2 (2) 1 (1) 1 (1) 1 (1)
Remained normal or shifted to normal 104 (90) 111 (94) 108 (89) 112 (93) 107 (91)
To high 11 (9) 5 (4) 13 (11) 7 (6) 9 (8)
Note: †n = 121.
*The urine cortisol population excluded any patients in the intent-to-treat population who had urine volumes of ,600 mL for females or ,800 mL for males and 24-hour 
creatinine excretion below the lower limit of the threshold range (defined as mean minus 2.5 SD, where the normal range was defined as the mean ± 2 SD); had a collection 
time interval outside the range of 24 ± 4 hours; used protocol-prohibited systemic or inhaled corticosteroids within eight weeks or protocol-prohibited intranasal or topical 
corticosteroids within four weeks before any start time of urine collection; and, for the end-of-study urinary cortisol measure, had not taken study medication for more than 
one day at the start time of urine collection. 
Abbreviation: SD, standard deviation.Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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weighted mean (treatment ratio 0.97, 95% CI 0.88–1.07). 
Fluticasone furoate did not differ from placebo with respect 
to 24-hour urinary cortisol excretion.
Together, these studies demonstrate that fluticasone 
furoate nasal spray at doses up to 400 µg daily for two weeks 
or 110 µg daily for six weeks did not affect hypothalamic-
pituitary-adrenal axis function. This result is consistent with 
the low systemic bioavailability (,0.5%) of fluticasone 
furoate nasal spray.
Growth
Exogenous corticosteroids can suppress growth via several 
possible mechanisms, including adrenal suppression with 
resultant subnormal androgen production, inhibition of 
growth hormone secretion and insulin-like growth factor-1 
bioactivity, and reduction of collagen synthesis.48 The risk 
of intranasal corticosteroid-associated systemic side effects 
such as growth suppression is low compared with that 
associated with the more bioavailable oral corticosteroids 
and older topical preparations such as betamethasone.50,51 
The effects of fluticasone furoate nasal spray on short-term 
growth were assessed in 53 prepubertal children (mean age 
9.1 years) with seasonal or perennial allergic rhinitis in a 
randomized, double-blind, placebo-controlled, crossover 
study.52 The two-week fluticasone furoate and placebo 
treatment periods were separated by a two-week washout 
period. The primary endpoint was lower leg growth rate 
assessed by knemometry. Fluticasone furoate did not affect 
lower leg growth rate versus placebo. Adjusted mean lower 
leg growth rate was 0.40 mm/week with fluticasone furoate 
and 0.42 mm/week with placebo. The difference between 
fluticasone furoate and placebo in adjusted mean lower leg 
growth rate was -0.016 mm/week (95% CI -0.13–0.10).
Nasal mucosal effects
Intranasal administration of corticosteroids is advantageous 
in that it delivers medication directly to the site of inflamma-
tion to maximize relief of nasal symptoms while minimizing 
the occurrence of systemic side effects. However, it is also 
potentially detrimental if it results in significant local side 
effects. The effects of fluticasone furoate nasal spray admin-
istered daily for one year on the nasal mucosa were examined 
in patients with perennial allergic rhinitis in a randomized, 
open-label study (GlaxoSmithKline protocol FFR104503).53 
Patients treated with fluticasone furoate 110 µg once daily 
(n = 37) or mometasone furoate nasal spray 200 µg once daily 
(n = 42) and a healthy control group (n = 17) that did not 
receive study medication underwent nasal biopsies at baseline 
and 12 months. The results show that fluticasone furoate 
nasal spray used daily for one year was not associated with 
nasal mucosal atrophy. Epithelial thickness did not change 
appreciably from baseline to 12 months in any group and 
did not differ between fluticasone furoate and mometasone 
furoate (least square mean difference -0.0008 mm, 95% 
CI -0.0075–0.0058; P = 0.802).
Summary
Considered in aggregate, these safety data demonstrate favor-
able topical and systemic safety of fluticasone furoate nasal 
spray administered daily for up to one year. The most common 
adverse events reported in short-term, controlled clinical 
trials were headache and epistaxis, which were reported 
with similar frequency for fluticasone furoate and placebo. 
During long-term treatment, epistaxis, which was most often 
mild, occurred more frequently with fluticasone furoate than 
placebo. This adverse event profile is consistent with that 
of other intranasal corticosteroids.31 No adverse effects on 
hypothalamic-pituitary-adrenal axis function or growth have 
been demonstrated in studies conducted to date. A placebo-
controlled study (clinicaltrials.gov identifier NCT00570492; 
GlaxoSmithKline protocol FFR101782) is being conducted 
to assess further the potential effects of fluticasone furoate 
110 µg once daily for one year on growth in pediatric patients 
aged 5–8 years with perennial allergic rhinitis.
Medical costs
Polypharmacy is common in allergic rhinitis. In a survey of 
447 patients with allergic rhinitis and their physicians, 56% 
reported use of two or more medications to control their 
allergic rhinitis.6 Comprehensive coverage of both nasal and 
ocular symptoms by fluticasone furoate nasal spray could 
potentially reduce the need for polypharmacy relative to 
agents that cover only nasal symptoms. The reduced need for 
polypharmacy would be expected to translate into a reduction 
in medical costs. This hypothesis was tested in a retrospective 
cohort analysis of pharmacy claims data from 793,349 patients 
with at least one claim for fluticasone furoate, budesonide, 
mometasone furoate, or triamcinolone acetonide from 1 April 
to 31 July 2007.54 At index, 62.9% of patients were using 
mometasone furoate, 21.1% triamcinolone acetonide, 15.1% 
budesonide, and 1.0% fluticasone furoate. (The low rate of 
use of fluticasone furoate is attributed to the fact that the study 
period occurred just after the drug’s introduction in the US 
in 2007.) Patients treated with fluticasone furoate compared 
with the other intranasal corticosteroids were 21% less likely 
to use concomitant prescription allergic rhinitis drugs (other Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
97
Fluticasone furoate in seasonal allergic rhinitis
than intranasal corticosteroids) and incurred significantly 
lower costs of concomitant allergic rhinitis drugs. The authors 
concluded that fluticasone furoate compared with the other 
intranasal corticosteroids in the study reduced the need for 
concomitant prescription allergic rhinitis medications and 
led to lower costs per patient with potentially significant 
savings for health plans.54
Patient perceptions  
vis-à-vis compliance
Patients’ self-reported willingness to comply with nasal spray 
therapy is strongly affected by several factors, including 
efficacy, safety, ease of use, comfort during administration, 
and sensory attributes such as the smell, taste, and aftertaste of 
a nasal spray.16,55  In a qualitative study involving one-on-one 
interviews with 24 physicians and 25 patients with allergic 
rhinitis, features identified as strengths of fluticasone furoate 
nasal spray included its appearance; its design, which makes 
it easier to hold and operate; side actuation, which facilitates 
control during drug administration; the fine, consistent mist; 
and the delivery nozzle, which feels comfortable in the nose.16 
The profile of fluticasone furoate nasal spray addresses many 
of these factors. First, as discussed above, fluticasone furoate 
nasal spray is effective and generally well tolerated with once 
daily use. Second, the fluticasone furoate delivery device, 
was designed to maximize ease of use and comfort during 
administration. These results are supported by qualitative 
assessments of the delivery device in patients in clinical trials.16 
Third, data suggest that the sensory attributes of fluticasone 
furoate also are conducive to patient compliance. In a crossover 
comparison of fluticasone furoate nasal spray and fluticasone 
propionate nasal spray in 127 patients with allergic rhinitis, 
patients preferred fluticasone furoate nasal spray over flutica-
sone propionate based on the attributes of odor (64% versus 
29%), taste (47% versus 21%), aftertaste (44% versus 22%), 
drip down the throat (43% versus 27%), and nose runoff (49% 
versus 19%).56
Compliance rates with fluticasone furoate nasal spray 
have not been systematically assessed in clinical practice, 
nor have compliance rates with fluticasone furoate nasal 
spray been directly compared with those of other intranasal 
corticosteroids. In clinical trials in which patients with peren-
nial allergic rhinitis were assigned to administer fluticasone 
furoate nasal spray or placebo once daily for six weeks, 
mean compliance rates ranged from 86% to 95%.26,27 In 
the 12-month, placebo-controlled safety study in patients 
with perennial allergic rhinitis (GlaxoSmithKline protocol 
FFR102123), 85% of fluticasone furoate-treated patients had 
$90% compliance, and an additional 10% had $80%–90% 
compliance.46 In these studies, compliance was assessed by 
patients’ indicating in a daily diary whether they had adminis-
tered two sprays of study medication into each nostril on each 
treatment day. Compliance was calculated for each patient as 
the number of days on which double-blind study medication 
was taken divided by the number of days of exposure to study 
treatment. Future research comparing compliance with flu-
ticasone furoate with that of other intranasal corticosteroids 
is warranted in light of the putative compliance-enhancing 
properties of fluticasone furoate.
Conclusions
The important attributes of fluticasone furoate in seasonal 
allergic rhinitis include low systemic bioavailability (,0.5%), 
onset of symptom relief as early as eight hours after initiation 
of treatment, 24-hour symptom relief with once-daily dosing, 
comprehensive coverage of both nasal and ocular symptoms, 
safety and tolerability with daily use, and availability in a device 
that could help enhance medication adherence. Fluticasone 
furoate nasal spray meets the present need for an intranasal 
corticosteroid with consistent efficacy for ocular symptoms in 
seasonal allergic rhinitis. Given the frequency and bothersome 
nature of ocular symptoms in allergic rhinitis,31 the consistent 
efficacy of fluticasone furoate nasal spray for ocular symptoms 
could prove to be important in reducing the need for polyphar-
macy, as suggested by the cohort analysis described earlier.54 
Furthermore, with a delivery device that improves the experience 
of medication delivery, fluticasone furoate could also prove to be 
unique in enhancing patient satisfaction and compliance.
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